PTTG3P promotes gastric tumour cell proliferation and invasion and is an indicator of poor prognosis
Weiwei Weng
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
These authors have contributed equally to this work.Search for more papers by this authorShujuan Ni
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
These authors have contributed equally to this work.Search for more papers by this authorYiqin Wang
Department of Pathology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
These authors have contributed equally to this work.Search for more papers by this authorMidie Xu
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Search for more papers by this authorQiongyan Zhang
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Search for more papers by this authorYusi Yang
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Search for more papers by this authorYong Wu
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Search for more papers by this authorQinghua Xu
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Search for more papers by this authorPeng Qi
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Search for more papers by this authorCong Tan
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Search for more papers by this authorDan Huang
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Search for more papers by this authorPing Wei
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Search for more papers by this authorZhaohui Huang
Wuxi Oncology Institute, the Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China
Search for more papers by this authorYuqing Ma
Department of Pathology, First Hospital Affiliated to Xinjiang Medical University, Urumqi, China
Search for more papers by this authorWei Zhang
Department of Pathology, First Hospital Affiliated to Xinjiang Medical University, Urumqi, China
Search for more papers by this authorCorresponding Author
Weiqi Sheng
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Correspondence to: Dr. Xiang DU M.D.
E-mail: [email protected]
Dr. Weiqi SHENG M.D., Ph.D.
E-mail: [email protected]
Search for more papers by this authorCorresponding Author
Xiang Du
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Department of Pathology, First Hospital Affiliated to Xinjiang Medical University, Urumqi, China
Institutes of Biomedical Sciences, Fudan University, Shanghai, China
Correspondence to: Dr. Xiang DU M.D.
E-mail: [email protected]
Dr. Weiqi SHENG M.D., Ph.D.
E-mail: [email protected]
Search for more papers by this authorWeiwei Weng
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
These authors have contributed equally to this work.Search for more papers by this authorShujuan Ni
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
These authors have contributed equally to this work.Search for more papers by this authorYiqin Wang
Department of Pathology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
These authors have contributed equally to this work.Search for more papers by this authorMidie Xu
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Search for more papers by this authorQiongyan Zhang
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Search for more papers by this authorYusi Yang
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Search for more papers by this authorYong Wu
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Search for more papers by this authorQinghua Xu
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Search for more papers by this authorPeng Qi
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Search for more papers by this authorCong Tan
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Search for more papers by this authorDan Huang
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Search for more papers by this authorPing Wei
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Search for more papers by this authorZhaohui Huang
Wuxi Oncology Institute, the Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China
Search for more papers by this authorYuqing Ma
Department of Pathology, First Hospital Affiliated to Xinjiang Medical University, Urumqi, China
Search for more papers by this authorWei Zhang
Department of Pathology, First Hospital Affiliated to Xinjiang Medical University, Urumqi, China
Search for more papers by this authorCorresponding Author
Weiqi Sheng
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Correspondence to: Dr. Xiang DU M.D.
E-mail: [email protected]
Dr. Weiqi SHENG M.D., Ph.D.
E-mail: [email protected]
Search for more papers by this authorCorresponding Author
Xiang Du
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Institute of Pathology, Fudan University, Shanghai, China
Department of Pathology, First Hospital Affiliated to Xinjiang Medical University, Urumqi, China
Institutes of Biomedical Sciences, Fudan University, Shanghai, China
Correspondence to: Dr. Xiang DU M.D.
E-mail: [email protected]
Dr. Weiqi SHENG M.D., Ph.D.
E-mail: [email protected]
Search for more papers by this authorAbstract
Pseudogenes play a crucial role in cancer progression. However, the role of pituitary tumour-transforming 3, pseudogene (PTTG3P) in gastric cancer (GC) remains unknown. Here, we showed that PTTG3P expression was abnormally up-regulated in GC tissues compared with that in normal tissues both in our 198 cases of clinical samples and the cohort from The Cancer Genome Atlas (TCGA) database. High PTTG3P expression was correlated with increased tumour size and enhanced tumour invasiveness and served as an independent negative prognostic predictor. Moreover, up-regulation of PTTG3P in GC cells stimulated cell proliferation, migration and invasion both in vitro in cell experiments and in vivo in nude mouse models, and the pseudogene functioned independently of its parent genes. Overall, these results reveal that PTTG3P is a novel prognostic biomarker with independent oncogenic functions in GC.
Supporting Information
| Filename | Description |
|---|---|
| jcmm13239-sup-0001-FigS1.tifimage/tif, 186.7 KB | Figure S1 The homologous sequences of PTTG3P, PTTG1, and PTTG2. Black represents the matched nucleotides among PTTG3P, PTTG1 and PTTG2, while white represents the differences |
| jcmm13239-sup-0002-FigS2.tifimage/tif, 7.8 MB | Figure S2 Verifying the qRT-PCR primers. (A) After designing specific primer sets for PTTG3P, PTTG1, and PTTG2, PCR was performed to verify the efficacy of the primers. (B) Sequencing the PCR product to verify the specificity of PTTG3P primers. (C) Sequencing the PCR product to verify the specificity of PTTG1 primers. (D) Sequencing the PCR product to verify the specificity of PTTG2 primers |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- 1Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: E359–86.
- 2Poliseno L, Salmena L, Zhang J, et al. A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature. 2010; 465: 1033–8.
- 3Chan WL, Yuo CY, Yang WK, et al. Transcribed pseudogene psiPPM1K generates endogenous siRNA to suppress oncogenic cell growth in hepatocellular carcinoma. Nucleic Acids Res. 2013; 41: 3734–47.
- 4Hayashi H, Arao T, Togashi Y, et al. The OCT4 pseudogene POU5F1B is amplified and promotes an aggressive phenotype in gastric cancer. Oncogene. 2015; 34: 199–208.
- 5Karreth FA, Reschke M, Ruocco A, et al. The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo. Cell. 2015; 161: 319–32.
- 6Mattoo AR, Zhang J, Espinoza LA, et al. Inhibition of NANOG/NANOGP8 downregulates MCL-1 in colorectal cancer cells and enhances the therapeutic efficacy of BH3 mimetics. Clin Cancer Res. 2014; 20: 5446–55.
- 7Puget N, Gad S, Perrin-Vidoz L, et al. Distinct BRCA1 rearrangements involving the BRCA1 pseudogene suggest the existence of a recombination hot spot. Am J Hum Genet. 2002; 70: 858–65.
- 8Chen L, Puri R, Lefkowitz EJ, et al. Identification of the human pituitary tumor transforming gene (hPTTG) family: molecular structure, expression, and chromosomal localization. Gene. 2000; 248: 41–50.
- 9Wang X, Duan W, Li X, et al. PTTG regulates the metabolic switch of ovarian cancer cells via the c-myc pathway. Oncotarget. 2015; 6: 40959–69.
- 10Bradshaw C, Kakar SS. Pituitary tumor transforming gene: an important gene in normal cellular functions and tumorigenesis. Histol Histopathol. 2007; 22: 219–26.
- 11Guo Y, Shao Y, Chen J, et al. Expression of pituitary tumor-transforming 2 in human glioblastoma cell lines and its role in glioblastoma tumorigenesis. Exp Ther Med. 2016; 11: 1847–52.
- 12Qi P, Xu MD, Shen XH, et al. Reciprocal repression between TUSC7 and miR-23b in gastric cancer. Int J Cancer. 2015; 137: 1269–78.
- 13Dong L, Qi P, Xu MD, et al. Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls. Int J Cancer. 2015; 137: 1128–35.
- 14Espinoza JA, Garcia P, Bizama C, et al. Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naive pT2 gallbladder adenocarcinoma patients. Histopathology. 2016; 68: 722–8.
- 15Xu MD, Dong L, Qi P, et al. Pituitary tumor-transforming gene-1 serves as an independent prognostic biomarker for gastric cancer. Gastric Cancer. 2016; 19: 107–15.
- 16Wang M, Xia X, Chu W, et al. Roles of miR-186 and PTTG1 in colorectal neuroendocrine tumors. Int J Clin Exp Med. 2015; 8: 22149–57.
- 17Liang HQ, Wang RJ, Diao CF, et al. The PTTG1-targeting miRNAs miR-329, miR-300, miR-381, and miR-655 inhibit pituitary tumor cell tumorigenesis and are involved in a p53/PTTG1 regulation feedback loop. Oncotarget. 2015; 6: 29413–27.
- 18Wang L, Guo ZY, Zhang R, et al. Pseudogene OCT4-pg4 functions as a natural micro RNA sponge to regulate OCT4 expression by competing for miR-145 in hepatocellular carcinoma. Carcinogenesis. 2013; 34: 1773–81.
- 19Esposito F, De Martino M, Petti MG, et al. HMGA1 pseudogenes as candidate proto-oncogenic competitive endogenous RNAs. Oncotarget. 2014; 5: 8341–54.
- 20Moreau-Aubry A, Le Guiner S, Labarriere N, et al. A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma. J Exp Med. 2000; 191: 1617–24.
- 21D'Errico I, Gadaleta G, Saccone C. Pseudogenes in metazoa: origin and features. Brief Funct Genomic Proteomic. 2004; 3: 157–67.
- 22Kandouz M, Bier A, Carystinos GD, et al. Connexin43 pseudogene is expressed in tumor cells and inhibits growth. Oncogene. 2004; 23: 4763–70.
Citing Literature
